BEAM

TentativeAI MemoPost-earnings T+3

Beam Therapeutics

As of 2026-08-14/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-14 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence

Action

—

Confidence

medium

Horizon

—

Key catalyst

BEAM-302 updated clinical data at ERS • 2026-11-12

Base target: $31 / p=50% prob

Biggest risk

The valuation remains dependent on clinical efficacy, safety, enrollment, regulatory execution, and eventual commercialization. No reliable Q2 EPS or revenue surprise versus consensus, post-print estimate revision, or target-price change is available in the packet. Recent CEO and CMO open-market sales are a sentiment overhang but do not establish an operating deterioration signal [#SEC-FORM4-2026-07-01][#SEC-FORM4-2026-07-29].

Invalidation

Break below $18 or thesis failure.

What would change my mind?

The post-Q2 operating update was constructive: Beam advanced BEAM-302 into a pivotal cohort, retained a mid-2029 cash runway, completed key BEACON dosing, and advanced BEAM-304 toward the clinic [#SEC-8K-2026-08-04]. These milestones support a cautiously positive pipeline thesis.

Research note

Recommendation

—

Confidence

medium

As of

2026-08-14

Base target

$31

p=50%

Bull target

$44

p=25%

Bear target

$18

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q2 execution and extended cash runway
Risto-cel data and potential BLA submission
Expansion of the liver-targeted pipeline

BearKey bullets

BEAM-302, BEAM-301, and BEAM-304 remain clinical-stage programs exposed to safety, efficacy, enrollment, and timing setbacks.
Cash runway into mid-2029 reduces near-term financing pressure but does not remove ongoing cash-burn and future-capital risk.
Recent open-market sales by the CEO and chief medical officer may weigh on sentiment, though insider activity is not evidence of operating results [#SEC-FORM4-2026-07-01][#SEC-FORM4-2026-07-29].

WatchKey bullets

BEAM-302 updated clinical data at ERS

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $31 (p=50%)

Target spread vs base: +42% / -42%

Scenario probabilities

Bull Target: $44 (p=25%)Base Target: $31 (p=50%)Bear Target: $18 (p=25%)

Commentary

The Q2 company update was operationally constructive, but this remains a milestone-driven monitoring thesis rather than an earnings-surprise thesis. The packet confirms the company source and major program milestones [#SEC-8K-2026-08-04], while trusted Q2 EPS/revenue surprise data, analyst revisions, target changes, and an isolated post-print price reaction are unavailable. Social coverage is absent; recent headlines are mixed because of secondary legal-dispute reporting.

As of 2026-08-14 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q2 execution and extended cash runway
Risto-cel data and potential BLA submission
Expansion of the liver-targeted pipeline

Scenarios

Bull Target (Scenario probability)

$44 / p=25% prob

Base Target (Scenario probability)

$31 / p=50% prob

Bear Target (Scenario probability)

$18 / p=25% prob

Analysis 2026-08-14 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-11-12
BEAM-302 updated clinical data at ERS
Updated BEAM-302 Phase 1/2 data were selected for a late-breaking oral presentation at the European Respiratory Society Congress, scheduled for September 5-9, 2026 [#SEC-8K-2026-08-04].
Prob 68.00% • Move 18.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

Q2 execution and extended cash runway
2026-08-04
Beam's Q2 2026 update confirmed first-patient dosing in the global pivotal BEAM-302 cohort, completed adult and adolescent BEACON dosing, cleared the BEAM-304 IND, and ended the quarter with $1.2 billion in cash, cash equivalents and marketable securities; management expects runway into mid-2029 [#SEC-8K-2026-08-04].
Prob 85% • Move 5% • Priced-in 80%

Long-term Catalysts

Months to a year

Risto-cel data and potential BLA submission
2026-12-31
Dosing is complete for adult and adolescent patients in the BEACON trial; Beam expects updated data by year-end 2026 and a U.S. BLA submission as early as year-end 2026 [#SEC-8K-2026-08-04].
Prob 55% • Move 25% • Priced-in 45%
Expansion of the liver-targeted pipeline
2026-12-31
BEAM-304 clinical start-up activities are underway after FDA IND clearance, while Beam expects initial BEAM-301 clinical data in 2026 [#SEC-8K-2026-08-04].
Prob 58% • Move 15% • Priced-in 35%

Risks

BEAM-302, BEAM-301, and BEAM-304 remain clinical-stage programs exposed to safety, efficacy, enrollment, and timing setbacks.
Cash runway into mid-2029 reduces near-term financing pressure but does not remove ongoing cash-burn and future-capital risk.
Recent open-market sales by the CEO and chief medical officer may weigh on sentiment, though insider activity is not evidence of operating results [#SEC-FORM4-2026-07-01][#SEC-FORM4-2026-07-29].
Risto-cel BLA timing is described as early as year-end 2026 and is not assured; regulatory or manufacturing delays could defer commercialization.
Secondary news coverage identifies an external gene-editing legal dispute involving Prime Medicine; the packet lacks a primary Beam source confirming its current financial or operational impact.

Peers

Symbol	Summary
AMGN	Large-cap biopharma benchmark, but materially larger and diversified, making direct valuation comparison weak.
RARE	Same-sector, similar-market-cap rare-disease biotech comparator; useful for milestone and clinical-execution framing, but not a direct base-editing peer.
NRIX	Similar-market-cap biotech candidate with program-driven valuation; a loose comparator for pipeline and financing risk rather than mechanism.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-14

Loading AI feed…

Symbol

Summary

AMGN

Large-cap biopharma benchmark, but materially larger and diversified, making direct valuation comparison weak.

RARE

Same-sector, similar-market-cap rare-disease biotech comparator; useful for milestone and clinical-execution framing, but not a direct base-editing peer.

NRIX

Similar-market-cap biotech candidate with program-driven valuation; a loose comparator for pipeline and financing risk rather than mechanism.